The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Open accessAbstract
Summary Background Despite increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the appropriate drug and dose, the need for retreatment, and the possibility of long-term systemic effects. We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therapy in treatment of ROP. Methods This randomised, open-label, superiority multicentre, three-arm, parallel group trial was done in 87 neonatal and ophthalmic centres in 26 countries. We screened infants with birthweight less than 1500 g who met criteria for treatment for retinopathy, and randomised patients equally (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0·2 mg or ranibizumab 0·1 mg, or laser therapy. Individuals were stratified by disease zone and geographical region using computer interactive response technology. The primary outcome was survival with no active retinopathy, no unfavourable structural outcomes, or need for a different treatment modality at or before 24 weeks (two-sided α=0·05 for superiority of ranibizumab 0·2 mg against laser therapy). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02375971. Interpretation Between Dec 31, 2015, and June 29, 2017, 225 participants (ranibizumab 0·2 mg n=74, ranibizumab 0·1 mg n=77, laser therapy n=74) were randomly assigned. Seven were withdrawn before treatment (n=1, n=1, n=5, respectively) and 17 did not complete follow-up to 24 weeks, including four deaths in each group. 214 infants were assessed for the primary outcome (n=70, n=76, n=68, respectively). Treatment success occurred in 56 (80%) of 70 infants receiving ranibizumab 0·2 mg compared with 57 (75%) of 76 infants receiving ranibizumab 0·1 mg and 45 (66%) of 68 infants after laser therapy. Using a hierarchical testing strategy, compared with laser therapy the odds ratio (OR) of treatment success following ranibizumab 0·2 mg was 2·19 (95% Cl 0·99−4·82, p=0·051), and following ranibizumab 0·1 mg was 1·57 (95% Cl 0·76−3·26); for ranibizumab 0·2 mg compared with 0·1 mg the OR was 1·35 (95% Cl 0·61−2·98). One infant had an unfavourable structural outcome following ranibizumab 0·2 mg, compared with five following ranibizumab 0·1 mg and seven after laser therapy. Death, serious and non-serious systemic adverse events, and ocular adverse events were evenly distributed between the three groups. Findings In the treatment of ROP, ranibizumab 0·2 mg might be superior to laser therapy, with fewer unfavourable ocular outcomes than laser therapy and with an acceptable 24-week safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Retinopathy of Prematurity Revisited
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.991 · Cited by 2,932
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1684 · Cited by 1,679
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007374 · Cited by 1,455
Gole, G. A., Ells, A. L., Katz, X., Holmström, G. E., Fielder, A. R., Capone, A., Flynn, J. T., Good, W., Holmes, J. M., McNamara, J. A., et al. (2005) · Archives of Ophthalmology · Cited by 1,386
Self-citation(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1769 · Cited by 1,001
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Blencowe, H., Lawn, J. E., Vazquez, T., Fielder, A., & Gilbert, C. (2013) · Pediatric Research · doi:10.1038/pr.2013.205 · Cited by 792
Self-citationMulticenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results
(1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130517027 · Cited by 759
Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.
Good, W. V. (2004) · PubMed · Cited by 571
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results
Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) · Pediatrics · doi:10.1542/peds.81.5.697 · Cited by 503
Cited by
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Metadata
- Authors
- Stahl, A., Lepore, D., Fielder, A., Fleck, B., Reynolds, J. D., Chiang, M. F., Li, J., Liew, M., Maier, R., Zhu, Q., & Marlow, N.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 394
- Issue
- 10208
- Pages
- 1551-1559
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2972706767
- Cited by
- 440
- References
- 21
- FWCI
- 27.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31344-3
- The paper
- Stahl, A., Lepore, D., Fielder, A., Fleck, B., Reynolds, J. D., Chiang, M. F., Li, J., Liew, M., Maier, R., Zhu, Q., & Marlow, N. (2019). Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31344-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.